Page 101 - HIV/AIDS Guidelines

11. Ribaudo H, Lennox J, Currier J, et al. Virologic failure endpoint definition in clinical trials: Is using HIV-1 RNA
threshold <200 copies/mL better than <50 copies/mL? An analysis of ACTG studies. Paper presented at: 16th
Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada. Abstract 580.
12. Lima V, Harrigan R, Montaner JS. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of
50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr.
2009;51(1):3-6.
13. Gatanaga H, Tsukada K, Honda H, et al. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients
with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin Infect Dis. 2009;48(2):260-262.
14. Willig JH, Nevin CR, Raper JL, et al. Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels
by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test. J Acquir Immune Defic Syndr.
2010;54(4):442-444.

15. Aleman S, Soderbarg K, Visco-Comandini U, et al. Drug resistance at low viraemia in HIV-1-infected patients with
antiretroviral combination therapy. AIDS. 2002;16(7):1039-1044.

16. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and
persistent low-level viremia. AIDS. 2004;18(7):981-989.

17. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving
HAART. JAMA. 2005;293(7):817-829.
18. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy
failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral
therapy. AIDS. 2009;23(9):1127-1134.
19. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
N Engl J Med. 2008;359(4):355-365.
20. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe
and Australia. N Engl J Med. 2003;348(22):2186-2195.
21. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North
and South America. N Engl J Med. 2003;348(22):2175-2185.
22. Reynes J, Arasteh K, Clotet B, et al. TORO: ninety-six-week virologic and immunologic response and safety evaluation
of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS. 2007;21(8):533-543.
23. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced
patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Lancet. 2007;369(9568):1169-1178.

24. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1
infection. N Engl J Med. 2008;359(4):339-354.
25. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients:
pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009;23(17):2289-2300.
26. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J
Med. 2008;359(14):1429-1441.
27. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N
Engl J Med. 2008;359(14):1442-1455.
28. Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with
multidrug-resistant HIV-1 infection. J Infect Dis. 2005;192(9):1537-1544.
29. Deeks SG, Lu J, Hoh R, et al. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on
an enfuvirtide-based regimen. J Infect Dis. 2007;195(3):387-391.
30. Wirden M, Simon A, Schneider L, et al. Raltegravir has no residual antiviral activity in vivo against HIV-1 with

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents H-8

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.